New German Study Ranks Mounjaro and Wegovy as Top Weight Loss Injections
A recent evaluation by Stiftung Warentest, Germany’s leading consumer organization, assessed the efficacy and safety of currently available weight loss medications, including Mounjaro, Saxenda, Wegovy, and Orlistat. The study, published this week, found that Mounjaro (tirzepatide) and Wegovy (semaglutide) demonstrated the most significant weight loss potential, though both carry potential side effects and require careful patient monitoring. This assessment arrives as demand for these medications surges globally, prompting scrutiny of their clinical benefits and accessibility.
In Plain English: The Clinical Takeaway
- These aren’t magic bullets: Weight loss injections perform best *with* a healthy diet and regular exercise. They help control appetite, but lifestyle changes are crucial.
- Mounjaro leads the pack: The study suggests Mounjaro shows the most promise for significant weight reduction, but Wegovy is similarly effective.
- Side effects are possible: Common side effects include nausea and digestive issues. More serious, though rarer, complications can occur, requiring medical attention.
The Mechanism: GLP-1 Receptor Agonists and Beyond
Mounjaro and Wegovy belong to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs mimic the effects of GLP-1, a naturally occurring hormone that regulates appetite and blood sugar levels. GLP-1 agonists work by slowing gastric emptying (how quickly food leaves the stomach), increasing feelings of fullness, and reducing food intake. Mounjaro, however, goes a step further. It’s a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. GIP also plays a role in appetite regulation and glucose metabolism, potentially contributing to Mounjaro’s superior efficacy. The precise interplay between GLP-1 and GIP is still under investigation, but research suggests a synergistic effect on weight loss and metabolic control. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407868/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407868/)
Clinical Trial Data and Efficacy Comparisons
The efficacy of tirzepatide (Mounjaro) has been demonstrated in the SURPASS-2 trial, a Phase 3 randomized, double-blind, placebo-controlled study involving over 2,400 adults with type 2 diabetes. Participants receiving tirzepatide experienced significant reductions in HbA1c (a measure of blood sugar control) and body weight compared to placebo. Specifically, those on the highest dose of tirzepatide (15mg) achieved an average weight loss of approximately 12.4 kg (27.4 lbs) over 72 weeks. Wegovy (semaglutide), studied in the STEP-1 trial, also showed substantial weight loss in obese or overweight adults without diabetes. Participants on semaglutide 2.4mg lost an average of 15.3 kg (33.7 lbs) over 68 weeks. However, a higher proportion of participants in the Wegovy trial reported gastrointestinal side effects leading to discontinuation. [https://www.nejm.org/doi/full/10.1056/NEJMoa2207290](https://www.nejm.org/doi/full/10.1056/NEJMoa2207290)
Geographical Access and Regulatory Landscape
Currently, Mounjaro is approved in the United States and Canada for the treatment of type 2 diabetes. Its approval for weight management is anticipated in the coming months, following positive Phase 3 trial results. In Europe, Wegovy is approved for weight management in several countries, including Germany, Denmark, and Norway. However, access remains limited due to manufacturing constraints and high demand. The European Medicines Agency (EMA) is currently reviewing data for tirzepatide for potential approval in the European Union. In the United States, the Food and Drug Administration (FDA) is expected to make a decision on Mounjaro for weight loss by the end of 2026. The National Health Service (NHS) in the UK is currently piloting programs to provide access to Wegovy for eligible patients, but widespread availability is still limited. The cost of these medications remains a significant barrier to access globally, with a monthly cost ranging from $900 to $1,300 USD.
Funding and Bias Transparency
It’s crucial to acknowledge the funding sources behind these trials. Both the SURPASS-2 (tirzepatide) and STEP-1 (semaglutide) trials were funded by pharmaceutical companies – Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy), respectively. While these companies adhere to rigorous clinical trial standards, potential for bias exists. Independent researchers emphasize the need for long-term, real-world studies to assess the sustained efficacy and safety of these medications outside of controlled trial settings.
“We need to move beyond the initial excitement and conduct robust post-market surveillance to understand the long-term effects of these drugs on cardiovascular health, liver function, and other vital organs,” states Dr. Emily Carter, an epidemiologist at the Centers for Disease Control and Prevention (CDC). “equitable access to these medications is paramount, and we must address the cost barriers that prevent many patients from benefiting from these advancements.”
Comparative Data: Efficacy and Side Effects
| Medication | Average Weight Loss (over 68-72 weeks) | Common Side Effects | Serious Adverse Events (Reported in Trials) |
|---|---|---|---|
| Mounjaro (Tirzepatide 15mg) | 12.4 kg (27.4 lbs) | Nausea, Vomiting, Diarrhea, Constipation | Pancreatitis, Gallbladder Problems (rare) |
| Wegovy (Semaglutide 2.4mg) | 15.3 kg (33.7 lbs) | Nausea, Vomiting, Diarrhea, Constipation | Pancreatitis, Gallbladder Problems, Thyroid Tumors (in animal studies) |
| Saxenda (Liraglutide 3.0mg) | 5-8 kg (11-18 lbs) | Nausea, Vomiting, Diarrhea, Constipation | Pancreatitis, Gallbladder Problems (rare) |
Contraindications & When to Consult a Doctor
These medications are not suitable for everyone. Individuals with a history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), or allergic reactions to GLP-1 receptor agonists should avoid these drugs. Pregnant or breastfeeding women should also not use them. Consult a doctor immediately if you experience severe abdominal pain, persistent nausea or vomiting, signs of gallbladder problems (such as jaundice), or any other concerning symptoms while taking these medications. Individuals with pre-existing kidney disease should be closely monitored, as these drugs can potentially affect kidney function. [https://www.fda.gov/drugs/safety-information/semaglutide-information](https://www.fda.gov/drugs/safety-information/semaglutide-information)
The Future of Obesity Treatment
The findings from Stiftung Warentest and the broader clinical landscape underscore a significant shift in obesity treatment. While lifestyle interventions remain the cornerstone of weight management, these injectable medications offer a powerful adjunct for individuals struggling with obesity and related health conditions. However, it’s crucial to approach these medications with realistic expectations and under the guidance of a qualified healthcare professional. Ongoing research is focused on developing even more effective and tolerable weight loss therapies, including combination drugs and novel targets within the metabolic pathway. The ultimate goal is to provide personalized treatment strategies that address the complex interplay of genetic, environmental, and behavioral factors contributing to obesity.
References
- Frias, J. P., et al. “Tirzepatide for Weight Management in Adults with Obesity.” New England Journal of Medicine, 2022.
- Wilding, J. P. H., et al. “Semaglutide for Weight Loss.” New England Journal of Medicine, 2021.
- U.S. Food and Drug Administration. “Semaglutide Information.”
- European Medicines Agency
- Centers for Disease Control and Prevention. “Obesity.”
